Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

10 Mar 2020

Abstract excerpt

Abstract Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32156747
DOI: 10.1158/1078-0432.ccr-19-3724

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerPMID 32156747Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Clinical Impact of Molecular Subtyping of Pancreatic CancerSemantic proximity Read ↗

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.Semantic proximity Read ↗

An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.Semantic proximity Read ↗

Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.Semantic proximity Read ↗

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.Semantic proximity Read ↗

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

<i>GATA6</i>amplification is associated with improved survival of<i>TP53</i>-mutated pancreatic cancerSemantic proximity Read ↗

A GATA6-centered gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancerSemantic proximity Read ↗

A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancerSemantic proximity Read ↗

Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep LearningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.